Another reminder ;)Medicago’s H5N1 VLP vaccine demonstrates cross-reactivity against multiple strains of avian flu
in key ferret animal model
Quebec City, Quebec, June 25, 2008 — Medicago Inc. (TSX-V: MDG) today announced additional positive results for
the Company's H5N1 Avian Influenza VLP vaccine from a preclinical immunogenicity study performed in ferrets, the
most predictive animal model for evaluating the effectiveness of influenza vaccines in humans. The Company’s H5N1
VLP vaccine induced high levels of antibodies that neutralized strains of H5N1 circulating virus beyond the strain used
to develop the original vaccine. Cross-reactivity was demonstrated against three of the deadliest strains of H5N1: the
Turkey strain (clade 2.2), the Anhui strain (clade 2.3) and the Vietnam strain (clade 1).
“These data further highlight the competitive advantages of our proprietary avian flu vaccine. Not only have we been
able to demonstrate the efficacy of our vaccine at very low doses, we have now demonstrated that our vaccine offers
broad protection against a variety of strains of this deadly virus,” said Andy Sheldon, President and CEO of Medicago.
“These unique properties, combined with the speed of our vaccine production platform, should prove highly attractive
to governments and institutions seeking to develop vaccine stockpiles and pandemic planning in the most efficient and
effective manner possible.”
From Ricky's article:
Avian flu virus: constantly mutating
...
It is known that there are 16 different HA (hemagglutinin) subtypes andnine NA (neuraminidase) subtypes of the avian influenza virus. Thesesubtypes can combine with each other, producing different subtypes ofthe disease. Because of these constant combinations of subtypes,producing vaccines becomes even more difficult. One can never know whatsubtype will emerge next, let alone what its impact will be.
PS.
timberlandmens boots has been injected throughout that article, I wouldn't click on the link, it may be malware.